TREVENTIS Corporation, a privately held biotechnology company, is thrilled to announce that it has entered an exciting option, collaboration, and license agreement with Takeda to explore the potential of small molecules that target tau, a key protein in Alzheimer’s Disease (AD).
This groundbreaking research could result in a disease-modifying mechanism for AD and other tauopathies by significantly reducing tau misfolding. It’s an exciting step forward in the effort to find a cure for this devastating condition.
Takeda and Treventis have entered into a strategic agreement to develop and commercialize a tau program, with the former having an exclusive option to license the program globally. As part of the arrangement, Treventis will receive research funding, an upfront payment, and the potential to receive up to $372.5 million in clinical and commercial milestone payments.
Additionally, Treventis will be eligible to receive tiered royalties on any potential net sales of a commercial product resulting from the license.
We are thrilled to announce our collaboration with Takeda to develop novel therapies for neurodegenerative diseases. Our Treventis tau program is the perfect complement to Takeda’s extensive experience and commercial presence in CNS drug development.
This partnership is a major milestone not only for our Common Conformational Morphology platform, but also for the advancement of Alzheimer’s Disease therapeutics.
Treventis scientists have developed a groundbreaking methodology for targeting misfolding proteins such as tau, which is an “intrinsically disordered protein” that has proven difficult to target with small molecules.
By leveraging epitope commonality between multiple misfolded proteins and creating Common Conformational Morphology (CCM) models of the earliest stages of protein misfolding, Treventis has developed a patented methodology for predicting and optimizing potent, drug-like compounds against tau. In addition, special assays are used to evaluate the speed of misfolding, allowing for more accurate targeting of tau.
TREVENTIS™ Corporation is on a mission to treat and prevent protein misfolding diseases. Our revolutionary discovery engine, Common Conformational Morphology (CCM), uses specialized in silico models to identify druggable active sites in misfolded proteins.
This cutting-edge technology has been used to develop novel treatments for tau, TDP isoforms, and other proteins associated with neurodegenerative diseases such as Alzheimer’s, frontotemporal dementia, and ALS. TREVENTIS also applies their technology platform to oncology for small molecule design, further demonstrating the broad utility of CCM in protein misfolding diseases.